Compare · BJDX vs QDEL
BJDX vs QDEL
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BJDX focuses on Medical/Dental Instruments, while QDEL focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances.
- QDEL is the larger of the two at $736.9M, about 252.8x BJDX ($2.9M).
- BJDX has been more active in the news (6 items in the past 4 weeks vs 3 for QDEL).
- QDEL has more recent analyst coverage (19 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- QuidelOrtho Corporation
- Price
- -
- -
- Market cap
- $2.9M
- $736.9M
- 1M return
- -
- -22.62%
- 1Y return
- -
- -49.04%
- Industry
- Medical/Dental Instruments
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 3
- Recent ratings
- 1
- 19
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest BJDX
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Latest QDEL
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- QuidelOrtho Reports Third Quarter 2026 Financial Results
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
- SEC Form 4 filed by QuidelOrtho Corporation
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
- QuidelOrtho Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits